EE05386B1 - Ftalasinoon-piperidinoderivaadid,ÁnendeÁkasutamineÁjaÁravim - Google Patents

Ftalasinoon-piperidinoderivaadid,ÁnendeÁkasutamineÁjaÁravim

Info

Publication number
EE05386B1
EE05386B1 EEP200300311A EEP200300311A EE05386B1 EE 05386 B1 EE05386 B1 EE 05386B1 EE P200300311 A EEP200300311 A EE P200300311A EE P200300311 A EEP200300311 A EE P200300311A EE 05386 B1 EE05386 B1 EE 05386B1
Authority
EE
Estonia
Prior art keywords
ánendeautomationajaarmedication
phthalazinone
piperidine derivatives
piperidine
derivatives
Prior art date
Application number
EEP200300311A
Other languages
English (en)
Estonian (et)
Inventor
Gerhardgrundler
Beate�Schmidt
Geert�Jan�Sterk
Armin�Hatzelmann
Daniela�Bundschuh
Hans-Peter�Kley
Hendrik�Timmerman
Johannes�A.�M.�Christiaans
Original Assignee
ALTANA�Pharma�AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ALTANA�Pharma�AG filed Critical ALTANA�Pharma�AG
Publication of EE200300311A publication Critical patent/EE200300311A/xx
Publication of EE05386B1 publication Critical patent/EE05386B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
EEP200300311A 2001-02-15 2002-02-14 Ftalasinoon-piperidinoderivaadid,ÁnendeÁkasutamineÁjaÁravim EE05386B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01103496 2001-02-15
PCT/EP2002/001547 WO2002064584A1 (en) 2001-02-15 2002-02-14 Phthalayinone-piperidino-derivatives as pde4 inhibitors

Publications (2)

Publication Number Publication Date
EE200300311A EE200300311A (et) 2003-10-15
EE05386B1 true EE05386B1 (et) 2011-02-15

Family

ID=8176497

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300311A EE05386B1 (et) 2001-02-15 2002-02-14 Ftalasinoon-piperidinoderivaadid,ÁnendeÁkasutamineÁjaÁravim

Country Status (22)

Country Link
US (3) US6953853B2 (cs)
EP (1) EP1362044A1 (cs)
JP (1) JP4301812B2 (cs)
KR (1) KR20030074817A (cs)
CN (1) CN1524080A (cs)
AU (1) AU2002234634B2 (cs)
BG (1) BG108124A (cs)
BR (1) BR0207278A (cs)
CA (1) CA2438520C (cs)
CZ (1) CZ20032491A3 (cs)
EA (1) EA200300836A1 (cs)
EE (1) EE05386B1 (cs)
HR (1) HRP20030636B1 (cs)
HU (1) HUP0303193A3 (cs)
IL (1) IL156812A0 (cs)
MX (1) MXPA03007310A (cs)
NO (1) NO325245B1 (cs)
NZ (1) NZ527424A (cs)
PL (1) PL363391A1 (cs)
SK (1) SK11382003A3 (cs)
WO (1) WO2002064584A1 (cs)
ZA (1) ZA200306815B (cs)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20030636B1 (en) 2001-02-15 2012-05-31 Nycomed Gmbh Phthalayinone-piperidino-derivatives as pde4 inhibitors
MXPA04002562A (es) * 2001-09-19 2004-05-31 Altana Pharma Ag Combinacion de un pde-4 y nsaid.
HRP20050197A2 (en) * 2002-08-10 2006-06-30 Altana Pharma Ag Piperidine-n-oxide-derivatives
WO2004018449A1 (en) * 2002-08-10 2004-03-04 Altana Pharma Ag Piperidine-derivatives as pde4 inhibitors
JP2005538140A (ja) * 2002-08-10 2005-12-15 アルタナ　ファルマ　アクチエンゲゼルシャフト Ｐｄｅ４インヒビターとしてのピペリジン−ピリダゾン及びフタラゾン
CA2494650A1 (en) * 2002-08-10 2004-03-04 Altana Pharma Ag Pyridazinone-derivatives as pde4 inhibitors
US20060148804A1 (en) * 2003-01-14 2006-07-06 Jurgen Braunger Pde4 inhibitors for the treatment of neoplasms of lymphoid cells
WO2004098606A1 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising a pde4 inhibitor and shuil-1r ii
WO2004098578A2 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
WO2004098605A1 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Pharmaceutical composition comprising a pde4 inhibitor and il-1 trap
WO2004098633A1 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising a pde-4 inhibitor and a tnf alpha antagonist
WO2004103407A2 (en) * 2003-05-22 2004-12-02 Altana Pharma Ag Composition comprising a pde4 inhibitor and a pde5 inhibitor
WO2005023253A1 (en) * 2003-09-05 2005-03-17 Altana Pharma Ag Use of pde4 inhibitors for the treatment of diabetes mellitus
AU2005210042B2 (en) * 2004-02-04 2011-04-21 Takeda Gmbh 2-(piperidin-4-yl) -4, 5-dihydro-2H-pyridazin-3-one derivatives as PDE4 inhibitors
US20080227790A1 (en) * 2004-02-04 2008-09-18 Altana Pharma Ag Pyridazinone Derivatives and their Use as Pde4 Inhibitors
WO2005075457A1 (en) * 2004-02-04 2005-08-18 Altana Pharma Ag Phthalazinone-derivatives as pde4 inhibitors
AU2006222060B2 (en) 2005-03-08 2011-09-01 Takeda Gmbh Roflumilast for the treatment of diabetes mellitus
ZA200804550B (en) 2005-11-09 2009-08-26 Combinatorx Inc Methods, compositions, and kits for the treatment of medical conditions
CA2637245A1 (en) * 2006-01-17 2007-07-26 Signal Pharmaceuticals, Llc Inhibitors of tnf.alpha., pde4 and b-raf, compositions thereof and methods of use therewith
ES2378281T3 (es) * 2006-07-05 2012-04-10 Nycomed Gmbh Combinación de atorvastatina con un inhibidor de fosfodiesterasa 4 para el tratamiento de neumopatías inflamatorias
AR064424A1 (es) * 2006-12-20 2009-04-01 Glaxo Group Ltd Derivados sustituidos de 1-oxo-ftalazinas y 1-oxo-pirido-piridazinas,composiciones farmaceuticas que los contienen y usos para prevenir y/o tratar enfermedades inflamatorias y alergicas del tracto respiratorio.
SI2148876T1 (sl) 2007-05-16 2012-01-31 Nycomed Gmbh Pirazolonski derivati kot PDE4 inhibitorji
AR074318A1 (es) 2008-11-14 2011-01-05 Nycomed Gmbh Derivados heterociclicos de pirazolona, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades de las vias respiratorias.
EP2721030B1 (en) * 2011-06-17 2015-12-16 Takeda GmbH Novel phthalazinone-pyrrolopyrimidinecarboxamide derivatives
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
EP3165224A1 (en) 2015-11-09 2017-05-10 Albert-Ludwigs-Universität Freiburg Use of pde4 inhibitors for the prophylaxis and/or therapy of dyslipoproteinaemia and related disorders
JP6820717B2 (ja) 2016-10-28 2021-01-27 株式会社日立ハイテク プラズマ処理装置
CN113121417A (zh) * 2019-12-30 2021-07-16 苏州盛迪亚生物医药有限公司 一种新型哌啶衍生物及其药物用途
WO2021192210A1 (ja) 2020-03-27 2021-09-30 株式会社日立ハイテク 半導体製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3245165B2 (ja) * 1991-10-09 2002-01-07 シンテックス（ユー・エス・エイ）・インコーポレイテッド ピリドピリダジノンおよびピリダジンチオン化合物
BR9307570A (pt) 1992-12-02 1999-05-25 Pfizer Diéteres de catecol como inibidores seletivos de pdeiv
DE19533975A1 (de) 1995-09-14 1997-03-20 Merck Patent Gmbh Arylalkyl-diazinone
ES2193508T3 (es) * 1997-01-15 2003-11-01 Altana Pharma Ag Ftalizinonas.
AU1760399A (en) * 1997-12-15 1999-07-05 Byk Gulden Lomberg Chemische Fabrik Gmbh New phthalazinones
ATE258930T1 (de) * 1997-12-15 2004-02-15 Altana Pharma Ag Dihydrobenzifurane
EP0934933A1 (en) 1998-02-06 1999-08-11 Byk Gulden Lomberg Chemische Fabrik GmbH Phthalazinones
DK1070056T3 (da) * 1998-03-14 2004-11-08 Altana Pharma Ag Phthalazinon-PDE III/IV-inhibitorer
WO2001019818A1 (en) 1999-09-14 2001-03-22 Byk Gulden Lomberg Chemische Fabrik Gmbh Phthalazinone derivatives as pd3/4 inhibitors
HUP0203487A2 (hu) * 1999-10-25 2003-02-28 Byk Gulden Lomberg Chemische Fabrik Gmbh Tetrahidrotiopirán-ftalazinon-származékok, mint PDE4-inhibitorok és ezeket tartalmazó gyógyszerkészítmények
EP1228046B1 (en) * 1999-10-25 2007-09-26 Nycomed GmbH Phthalazinone derivatives as pde 4 inhibitors
CZ20023997A3 (cs) 2000-06-05 2003-05-14 Altana Pharma Ag Pyridazinonové deriváty
HRP20030636B1 (en) * 2001-02-15 2012-05-31 Nycomed Gmbh Phthalayinone-piperidino-derivatives as pde4 inhibitors
EE200300514A (et) 2001-04-25 2004-02-16 Altana Pharma Ag Ftalasinoonid, nende kasutamine hingamisteede haigusnähte leevendavate ravimite valmistamiseks ningneid sisaldavad ravimid
JP4021329B2 (ja) 2001-04-25 2007-12-12 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング ピペラジノ誘導体およびｐｄｅ４阻害剤としてのその使用
HRP20050197A2 (en) 2002-08-10 2006-06-30 Altana Pharma Ag Piperidine-n-oxide-derivatives
JP2005538140A (ja) 2002-08-10 2005-12-15 アルタナ　ファルマ　アクチエンゲゼルシャフト Ｐｄｅ４インヒビターとしてのピペリジン−ピリダゾン及びフタラゾン
CA2494650A1 (en) 2002-08-10 2004-03-04 Altana Pharma Ag Pyridazinone-derivatives as pde4 inhibitors

Also Published As

Publication number Publication date
CA2438520C (en) 2011-10-04
US20050234062A1 (en) 2005-10-20
US7531540B2 (en) 2009-05-12
HUP0303193A2 (hu) 2003-12-29
HRP20030636B1 (en) 2012-05-31
HUP0303193A3 (en) 2007-08-28
EE200300311A (et) 2003-10-15
US20070129373A1 (en) 2007-06-07
HRP20030636A2 (en) 2005-06-30
PL363391A1 (en) 2004-11-15
US7179810B2 (en) 2007-02-20
BG108124A (bg) 2004-08-31
CN1524080A (zh) 2004-08-25
NO325245B1 (no) 2008-03-10
NO20033618L (no) 2003-10-15
WO2002064584A1 (en) 2002-08-22
EA200300836A1 (ru) 2004-02-26
US20040067946A1 (en) 2004-04-08
CZ20032491A3 (cs) 2004-01-14
JP2004518727A (ja) 2004-06-24
JP4301812B2 (ja) 2009-07-22
SK11382003A3 (sk) 2004-01-08
ZA200306815B (en) 2004-06-17
US6953853B2 (en) 2005-10-11
CA2438520A1 (en) 2002-08-22
KR20030074817A (ko) 2003-09-19
BR0207278A (pt) 2004-02-10
IL156812A0 (en) 2004-02-08
NZ527424A (en) 2005-02-25
MXPA03007310A (es) 2003-12-04
NO20033618D0 (no) 2003-08-14
EP1362044A1 (en) 2003-11-19
AU2002234634B2 (en) 2007-07-26

Similar Documents

Publication Publication Date Title
DE60214428D1 (de) 1, 4-dihydro-1, 4-diphenylpyridin-derivate
DE50210707D1 (de) Substituierte 2-pyridin-cyclohexan-1,4-diaminderivate
DE60225563D1 (de) 4-amino-6-phenyl-pyrroloä2,3-düpyrimidin derivate
ATE319451T1 (de) Tetrahydrochinolin-derivate
DK1427709T3 (da) 3-substituerede 4-pyrimidonderivater
DE60216115D1 (de) BENZIMIDAZO 4,5-föISOCHINOLINON-DERIVATE
LTC1633724I2 (lt) Ftalazinono dariniai
NO20034970D0 (no) Nye arylheteroalkylaminderivater
DE50208022D1 (de) Wischblatt
EE200300447A (et) Asendatud bensofuraan-2-karboksamiidide derivaadid
ATE414056T1 (de) Substituierte c-cyclohexylmethylamin-derivative
DE50107988D1 (de) Substituierte 1,2,3,4-tetrahydrochinolin-2-carbonsäurederivate
DE60223031D1 (de) Arylpiperazin gebundene tetrahydroindolonderivate
ATE282021T1 (de) Substituierte aminomethyl-phenyl- cyclohexanderivate
ATE272045T1 (de) Substituierte 1-aminobutan-3-ol-derivate
NO20042980L (no) 3,4-dihydro-1H-isokinolin-2-yl-derivater
NO20035248D0 (no) Nye fenylalkyloksy-fenyl derivater
ATE382601T1 (de) Substituierte 4-aminocyclohexanolderivate
DK1330442T3 (da) Phthalazinon-derivativer
ITMI20022183A1 (it) Cerniera.
NO20044405L (no) Neurotensinaktive 2,3-diaryl-pyrazolidin derivater
DE60202381D1 (de) Paroxetin-n-formyl-derivate
IS7022A (is) Nýjar indólafleiður
ATE361274T1 (de) Substituierte 5-amino-1-penten-3-ol-derivate
IS7131A (is) Nýjar 2,4-díamínóþíasól afleiður

Legal Events

Date Code Title Description
HC1A Change of owner name
HC1A Change of owner name
MM4A Lapsed by not paying the annual fees

Effective date: 20140214